The price of ITeos Therapeutics Inc (NASDAQ:ITOS) shares last traded on Wall Street rose 0.20% to $10.18.
ITOS stock price is now 15.03% away from the 50-day moving average and 24.14% away from the 200-day moving average. The market capitalization of the company currently stands at $389.63M.
With the price target maintained at $12, Wells Fargo recently Downgraded its rating from Overweight to Equal Weight for ITeos Therapeutics Inc (NASDAQ: ITOS). On May 28, 2025, Wedbush Downgraded its previous ‘Outperform’ rating to ‘Neutral’ on the stock keeping its target price maintained at $12, while ‘Leerink Partners’ rates the stock as ‘Market Perform’
In other news, Detheux Michel, Chief Executive Officer sold 43,882 shares of the company’s stock on Jun 09 ’25. The stock was sold for $440,136 at an average price of $10.03. Upon completion of the transaction, the Chief Executive Officer now directly owns 0 shares in the company, valued at $0.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 10 ’25, Chief Executive Officer Detheux Michel sold 43,883 shares of the business’s stock. A total of $439,708 was realized by selling the stock at an average price of $10.02. A total of 6.26% of the company’s stock is owned by insiders.
During the past 12 months, ITeos Therapeutics Inc has had a low of $4.80 and a high of $18.13. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 14.13, and a quick ratio of 14.13. The fifty day moving average price for ITOS is $8.8502 and a two-hundred day moving average price translates $8.200675 for the stock.
The latest earnings results from ITeos Therapeutics Inc (NASDAQ: ITOS) was released for 2025-03-31. The net profit margin was -373.75% and return on equity was -23.68% for ITOS.
